Estudo da caracterização imunofenotípica de pacientes idosos com leucemia mielóide aguda no Rio Grande do Norte
Acute Myeloid Leukemia (AML) is the most frequent leukemia in adult over 60 years of age in more than 50% of the cases represented 15 to 20% of childhood leukemias and 80% of adult leukemias, with a poor prognosis, especially in elderly patients. The Myelodysplastic Syndromes (MDS) comprise another...
| Autor: | |
|---|---|
| Tipo de recurso: | tesis de maestría |
| Estado: | Versión publicada |
| Fecha de publicación: | 2016 |
| País: | Brasil |
| Institución: | Universidade Federal do Rio Grande do Norte (UFRN) |
| Repositorio: | Repositório Institucional da UFRN |
| Idioma: | portugués |
| OAI Identifier: | oai:repositorio.ufrn.br:123456789/27244 |
| Acceso en línea: | https://repositorio.ufrn.br/jspui/handle/123456789/27244 |
| Access Level: | acceso abierto |
| Palabra clave: | Leucemia Mielóide Aguda Sindrome Mielodisplásica Imunofenotipagem Idosos Prognóstico CNPQ::CIENCIAS DA SAUDE::FARMACIA |
| Sumario: | Acute Myeloid Leukemia (AML) is the most frequent leukemia in adult over 60 years of age in more than 50% of the cases represented 15 to 20% of childhood leukemias and 80% of adult leukemias, with a poor prognosis, especially in elderly patients. The Myelodysplastic Syndromes (MDS) comprise another spectrum of acute clonal cancers that also involve mainly older age group of individuals and are characterized by ineffective hematopoiesis, peripheral cytopenia, chromosomal abnormalities and a variable predilection of progression to AML. Elderly patients with Acute Myeloid Leukemia (AML) is part of a biological and clinically distinct group having a decreased response to chemotherapy. This study aimed to carry out an investigative study of Acute Myeloid Leukemias in a group of elderly patients at the diagnosis, to determine the clinical and biological characteristics of these leukemias. The data analysis showed that 56 patients had newly diagnosed AML (70%) 6 with recurrent disease (7.5%), 15 had transformed MDS (18.7%) and refractory AML 3 (3.7%). About clinical aspects, there was a predominance of splenomegaly (91.2%), followed by hepatomegaly (76.2%). Laboratory findings showed predominance of hyperleukocytosis (91.3%), thrombocytopenia (85%) and anemia (86.2%). Most cases had FAB classification M1 (36.6%), M2 (17.5%) and M4 (23.7%). Our Data analysis was statistically significant (p <0.05) and showed correlation of CD7 (25%), PgP (45%), p53 (30%) and Bcl-2 (30%) with increasing disease status, likely contributing to a worse prognosis in this group of patients. Our results demonstrate the importance of clinical and laboratory investigation of these groups of patients in order to obtain more information about these cancers. This work was submitted to the ethics committee of the University Hospital Onofre Lopes and obtained approval under number 359/09. |
|---|